Drug intelligence / Profile preview

Hspb1 siRNA

Development stage
Preclinical
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Intraperitoneal, Intratumoral, Transfection, Nanoparticle Encapsulation
01

Overview

Small interfering RNA targeting Hspb1 is an experimental RNA interference (RNAi) therapeutic designed to silence the expression of the Hspb1 gene (also known as Heat Shock Protein 27 or HSP27). Hspb1 is a molecular chaperone that plays a critical role in protecting cells from stress and acts as a negative regulator of ferroptosis, an iron-dependent form of regulated cell death. In the context of hepatocellular carcinoma (HCC), Hspb1 is often upregulated and contributes to treatment resistance. By utilizing siRNA to downregulate Hspb1, researchers aim to trigger ferroptosis, disrupt lipid metabolism, and sensitize tumors to radiotherapy and immune checkpoint inhibitors (such as anti-PD-1 therapy). Preclinical studies indicate that this approach not only directly inhibits tumor growth but also promotes a more robust anti-tumor immune response by increasing the infiltration of cytotoxic CD8+ T cells into the tumor microenvironment.

Other names
Hspb1 siRNAHspb-1 siRNAHspb 1 siRNAHSP27 siRNAHSP-27 siRNAHSP 27 siRNAsmall interfering RNA targeting Heat shock protein beta-1siRNA targeting Hspb1
02

Targets

HSPB1 (Heat shock protein beta-1)

Beyond the preview

Go deeper on Hspb1 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hspb1 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call